Long-term efficacy, safety of DMTs in MS

 

SPECIAL REPORT

7TH JOINT ECTRIMS-ACTRIMS MEETING – October 25-28, 2017

Teriflunomide
Dimethyl fumarate
Fingolimod
Alemtuzumab

An accumulating body of evidence has indicated that sustained treatment with a disease-modifying therapy (DMT) can improve relapse recovery and slow the accumulation of disability in patients with relapsing MS.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page